Rosen Law Firm Investigating ADMA Biologics Securities Class Action

Firm encourages investors to inquire about potential lawsuit over stock performance.

Apr. 2, 2026 at 12:26am

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a global investor rights law practice, announced it is investigating potential securities claims on behalf of shareholders of ADMA Biologics, Inc. The investigation focuses on whether the company and its officers made false and misleading statements or failed to disclose material information regarding ADMA's business, operations, and prospects.

Why it matters

ADMA Biologics is a commercial biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics. The Rosen Law Firm's investigation could lead to a class action lawsuit, which could impact ADMA's stock price and investor confidence in the company.

The details

The Rosen Law Firm is encouraging ADMA Biologics investors to contact the firm to discuss the investigation and their potential claims. The investigation is focused on determining if ADMA and its executives issued false or misleading statements or failed to disclose material information about the company's business and financial condition.

  • The Rosen Law Firm announced the investigation on April 1, 2026.

The players

Rosen Law Firm

A global investor rights law practice that specializes in representing investors in securities class actions and shareholder derivative litigation.

ADMA Biologics, Inc.

A commercial biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics.

Got photos? Submit your photos here. ›

What’s next

The Rosen Law Firm is encouraging ADMA Biologics investors to contact the firm to discuss the investigation and their potential claims.

The takeaway

This investigation by the Rosen Law Firm highlights the importance of transparency and accurate disclosure for publicly traded companies like ADMA Biologics. Investors will be closely watching to see if the investigation leads to a class action lawsuit that could impact the company's stock price and reputation.